Advancing access to myeloma treatment: administration, side effects, and implications for survival.
Davies
Marianne J
MJ
Yale University School of Medicine, Section of Medical Oncology, Yale Cancer Center, New Haven, CT, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D017024:Chemotherapy, Adjuvant; D006297:Health Services Accessibility; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007255:Information Services; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D024802:Nurse's Role; D009859:Oncology Nursing / Q000458:organization & administration*; D010353:Patient Education as Topic; D011480:Protease Inhibitors / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant; D033581:Stem Cell Transplantation / Q000379:methods / Q000451:nursing; D015996:Survival Rate; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001897:Boronic Acids; D007166:Immunosuppressive Agents; D011480:Protease Inhibitors; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide